Focus: Glaukos is a publicly traded ophthalmology-focused medical device and specialty pharma company headquartered in Aliso Viejo, CA, specializing in glaucoma treatment devices and corneal cross-linking therapies. The company generates approximately $315M in annual revenue with a portfolio spanning micro-bypass stents, intracameral implants, and ophthalmic solutions.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Glaukos to get notified when they start hiring — the background below is worth knowing for when they do.
Generic post-LOE product generating minimal Part D revenue; represents legacy portfolio erosion.
Help build intelligence for Glaukos
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Glaukos's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Duplicate ANDA entry; legacy portfolio contributor with minimal ongoing revenue.
Patent cliff approaching May 2029; part of concentrated mitomycin revenue base at risk.
Flagship corneal cross-linking formulation at peak commercial maturity; key differentiator in keratoconus and corneal ectasia markets.
Additional generic ANDA entry; commoditized portfolio asset with no strategic value.
Next-generation intracameral implant in growth phase with LOE protection through 2031; core next-gen pipeline asset driving recent investor optimism.
Duplicate dextran formulation entry; core cross-linking franchise sustaining revenue.
Branded mitomycin NDA approaching LOE; part of concentrated revenue cliff risk in oncology-ophthalmology overlap.
Corneal cross-linking kit approaching LOE in October 2028; part of secondary formulation portfolio.
Additional generic ANDA entry; further evidence of portfolio concentration in commoditized mitomycin space.
2 discontinued, 6 duplicate formulations not shown
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 Business Wire
Glaukos Corp stock and its role in eye disease treatment - Ad Hoc News
Glaukos Corp stock and its role in eye disease treatment Ad Hoc News
Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus - Ad Hoc News
Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus Ad Hoc News
Glaukos Announces Participation in Upcoming Investor Conferences - pharmiweb.com
Glaukos Announces Participation in Upcoming Investor Conferences pharmiweb.com
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars - International Business Times Australia
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars International Business Times Australia
Glaukos Announces First Quarter 2026 Financial Results - Business Wire
Glaukos Announces First Quarter 2026 Financial Results Business Wire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo